Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.

Revenue
+4.15%
EPS
+49.0%
Free cash flow
+49.8%
Total debt
+80.0%

Quarter to September 2026, against a year earlier

209.82 16.72 −7.38%
Market cap
$31.5B
P/E
35.6×
Fwd P/E
46.4×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. (ILMN) Revenue growth

Alert me on Revenue growth

Illumina, Inc.'s revenue growth over the twelve months to 30 September 2026 was 5.83%, up 6.5 percentage points from fiscal 2025 (−0.66%). Over the past ten years it has ranged from −8.58% (fiscal 2020) to 39.7% (fiscal 2021); the current reading is higher than 36% of that period. That is below the Diagnostics & Research industry median of 8.99% and below the Healthcare sector median of 7.80%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 −0.66% 2.27
FY2024 −2.93% (1.18)
FY2023 −1.75% (3.03)
FY2022 1.28% (38.45)
FY2021 39.7% 48.31
FY2020 −8.58% (14.88)
FY2019 6.30% (14.81)
FY2018 21.1% 6.35
FY2017 14.8% 6.74
FY2016 8.02% (11.25)

Quarterly newest first

Period Revenue growth Change (points)
Sep 2026 4.15% (5.29)
Jun 2026 9.44% 4.64
Mar 2026 4.80% (0.18)
Dec 2025 4.98% 4.61
43 more quarters

Against its own ten years

Low −8.58% High 39.7%
Ten-year median 6.30%
Current reading's percentile 36

Revenue growth against peers

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on ILMN